

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

PPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
10/069,799	07/19/2002	Jacinta Farn	20-02	3899	
23713	7590 07/07/2005		EXAM	EXAMINER	
GREENLEE WINNER AND SULLIVAN P C			BASKAR, PA	BASKAR, PADMAVATHI	
4875 PEARL SUITE 200	EAST CIRCLE		ART UNIT	PAPER NUMBER	
BOULDER, CO 80301			1645		

DATE MAILED: 07/07/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/069,799	FARN ET AL.		
Examiner	Art Unit	•	
Padmavathi v. Baskar	1645		

İ	Padmavathi v. Baskar	1645	
The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence add	ress
THE REPLY FILED FAILS TO PLACE THIS APPLICAT	ION IN CONDITION FOR ALLOWA	ANCE.	
 The reply was filed after a final rejection, but prior to or o this application, applicant must timely file one of the folloplaces the application in condition for allowance; (2) a No (3) a Request for Continued Examination (RCE) in comp following time periods: 	n the same day as filing a Notice of wing replies: (1) an amendment, a otice of Appeal (with appeal fee) in	f Appeal. To avoid at ffidavit, or other evide compliance with 37 (ence, which CFR 41.31; or
a) The period for reply expiresmonths from the mailing of	date of the final rejection.		
b) The period for reply expires on: (1) the mailing date of this Advevent, however, will the statutory period for reply expire later the Examiner Note: If box 1 is checked, check either box (a) or (b) MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f	an SIX MONTHS from the mailing date of ONLY CHECK BOX (b) WHEN THE FI	the final rejection.	
Extensions of time may be obtained under 37 CFR 1.136(a). The date on been filed is the date for purposes of determining the period of extension a CFR 1.17(a) is calculated from: (1) the expiration date of the shortened standard in the shortened in the shortened patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	and the corresponding amount of the fee. atutory period for reply originally set in the	The appropriate extension final Office action; or (2)	n fee under 37 as set forth in (b)
 The Notice of Appeal was filed on 18 April 2005. A brief date of filing the Notice of Appeal (37 CFR 41.37(a)), or appeal. Since a Notice of Appeal has been filed, any replacements. 	any extension thereof (37 CFR 41.3	37(e)), to avoid dismi	ssal of the
3. \square The proposed amendment(s) filed after a final rejection,	but prior to the date of filing a brief	f, will <u>not</u> be entered	because
 (a) ☐ They raise new issues that would require further co (b) ☐ They raise the issue of new matter (see NOTE below) (c) ☐ They are not deemed to place the application in be 	ow);	•	the issues for
appeal; and/or (d)☐ They present additional claims without canceling a			
NOTE: (See 37 CFR 1.116 and 41.33(a))	•		
4. The amendments are not in compliance with 37 CFR 1. 5. Applicant's reply has overcome the following rejection(s		ompliant Amendment	(PTOL-324).
6. Newly proposed or amended claim(s) would be a the non-allowable claim(s).	• ——	, timely filed amendm	ent canceling
7. A For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is proof The status of the claim(s) is (or will be) as follows:	☐ will not be entered, or b) ☒ worlded below or appended.	ill be entered and an	explanation of
Claim(s) allowed: <u>63 and 66.</u> Claim(s) objected to: <u>NONE</u> .			
Claim(s) rejected: <u>72</u> . Claim(s) withdrawn from consideration: <u>NONE</u> .			
AFFIDAVIT OR OTHER EVIDENCE			
8. The affidavit or other evidence filed after a final action, b because applicant failed to provide a showing of good ar and was not earlier presented. See 37 CFR 1.116(e).			
9. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to showing a good and sufficient reasons why it is necessar	overcome <u>all</u> rejections under appe	al and/or appellant fa	ils to provide a
10. ☐ The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	on of the status of the claims after e	entry is below or attac	ched.
 The request for reconsideration has been considered busee attached. 			
12. Note the attached Information Disclosure Statement(s). 13. Other:	(PTO/SB/08 or PTO-1449) Paper	No(s)	
10. 🗀 Other		MARK NA\ PRIMARY E)	/ARRO (AMINER

Applicant's amendment filed on 3/18/05 is entered.

Status of Claims

- Claims 1-62, 64-65, 67-71 and 73-84 have been canceled Claims 63 and 72 have been amended.
 Claims 63, 66 and 72 are pending in the application.
- 3. In view of amendment to the claims, the rejections under 35 U.S.C. 112, first paragraph and art rejections of record for claims 63 and 66 are withdrawn.
- 4. The rejection of claim 72 under 35 U.S.C. 112 first paragraph is maintained as set forth in the previous office action.

'Applicant's arguments have been considered but found to be not persuasive.

Applicant states that overlapping peptides are well known and once the amino acid sequence is known, it is routine in the art to synthesize a series of overlapping peptides and immunize the animals for producing antibodies and screen the peptides for specificity for the given peptide.

The examiner disagrees with the applicant because the ability of a given oligopeptide to elicit antibody responses that react with the native molecule currently is unpredictable at best. One reason is that oligopeptides only have the ability to represent linear or "continuous" epitopes. "Discontinuous" epitopes are composed of sequences from throughout an antigen and rely on folding of the protein to bring the sequences into close proximity of one another. Clearly, oligopeptides are incapable of representing such epitopes. Moreover, even though continuous epitopes are structurally less complicated than discontinuous ones, there remains only a poor understanding of how the immune system recognizes and responds to these antigenic species.

5. The rejection of claim 72 under 35 U.S.C. 102(e) as being anticipated by Campos et al U.s.patent: 6,096,320 is maintained as set forth in the previous office action.

The rejection of claim 72 under 35 U.S.C. Billson, F. M. et al. (1994) FEMS Microbiology 124:69-73 is maintained as set forth in the previous office action.

Applicant states that Campos reference teaches leukotoxin of P.haemolytica and Billson discloses haemolysin antigen from the M.bovis UQV148 NF and thus do not disclose recombinant polypeptide of M.bovis or SEQ.ID.NO:5 fragments.

The examiner disagrees with the applicant because the limitations which applicant is arguing about, are not set forth in the claim 72. In addition the prior art fragment is 100% identical to the claimed fragments. Therefore, the rejections for claim 72 are maintained.

6. Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Padma Baskar Ph.D., whose telephone number is ((571) 272 0853. A message may be left on the Examiner's voice mail system. The Examiner can normally be reached on Monday to Friday from 6.30 a.m. to 4.00 p.m. except First Friday of each bi week.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lynette Smith can be reached on (571) 272-0864. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (571) 272-1600.

Padma Baskar Ph.D.